Secretome of Hypoxia-Preconditioned Mesenchymal Stem Cells Ameliorates Hyperglycemia in Type 2 Diabetes Mellitus Rats

Trends in Sciences Pub Date : 2024-03-01 DOI:10.48048/tis.2024.7278

Wita Widyaningsih, Agung Putra, Sri Priyantini, A. Muhar, Titiek Sumarawati, S. Trisnadi, N. Amalina, I. Alif, Ardi Prasetio, Risky Chandra Satria Irawan

{"title":"Secretome of Hypoxia-Preconditioned Mesenchymal Stem Cells Ameliorates Hyperglycemia in Type 2 Diabetes Mellitus Rats","authors":"Wita Widyaningsih, Agung Putra, Sri Priyantini, A. Muhar, Titiek Sumarawati, S. Trisnadi, N. Amalina, I. Alif, Ardi Prasetio, Risky Chandra Satria Irawan","doi":"10.48048/tis.2024.7278","DOIUrl":null,"url":null,"abstract":" Introduction: Type 2 diabetes mellitus (T2DM) is a prevalent form of diabetes that affects 90 - 95 % of all diabetic patients. Insulin sensitizers and insulin exogenous supply could temporarily ameliorate hyperglycaemia; however, they are accompanied by side effects. As a result, new approaches are required to address insulin resistance and regenerate beta cells simultaneously. The secretome of hypoxic mesenchymal stem cells (SH-MSCs) contains various growth factors and anti-inflammatory cytokines that could potentially enhance insulin resistance and improve pancreatic function. Objectives: In this study, we performed SH-MSCs infusion to ameliorate HFD-induced hyperglycaemia in T2DM rats. Methods: We created a T2DM rat model using a combination of a high-fat diet (HFD) and streptozotocin (STZ) administration. Then, we administered SH-MSCs injection at doses of 250 and 500 µL and assessed the therapeutic effects of SH-MSCs. We also investigated the potential underlying mechanisms involved. Results: The administration of SH-MSCs improved hyperglycemia in rats with T2DM. Infusion of SH-MSCs at 500 µL dose decreased homeostatic model assessment for insulin resistance (HOMA-IR). Histological analysis revealed that injection of SH-MSCs alleviated morphological damage of pancreas. SH-MSCs administration also inhibit the level of IL-6 and promote the expression of CD163 type 2 macrophage. Conclusion: The results of our study indicate that SH-MSCs have the potential to improve hyperglycemia and exert a protective effect on T2DM rats.\nHIGHLIGHTS\n \n\nAdministration of SH-MSCs effectively improved hyperglycemia and decreased insulin resistance in TD2M rats through modulation of IL-6 levels and promotes the expression of CD163 type 2 macrophage\nHistological analysis demonstrated the protective effect of SH-MSCs on pancreatic morphology\nSH-MSCs hold promise for improving hyperglycemia, insulin resistance, and providing a protective effect in TD2M\n\nGRAPHICAL ABSTRACT\n","PeriodicalId":513497,"journal":{"name":"Trends in Sciences","volume":"74 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48048/tis.2024.7278","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) is a prevalent form of diabetes that affects 90 - 95 % of all diabetic patients. Insulin sensitizers and insulin exogenous supply could temporarily ameliorate hyperglycaemia; however, they are accompanied by side effects. As a result, new approaches are required to address insulin resistance and regenerate beta cells simultaneously. The secretome of hypoxic mesenchymal stem cells (SH-MSCs) contains various growth factors and anti-inflammatory cytokines that could potentially enhance insulin resistance and improve pancreatic function. Objectives: In this study, we performed SH-MSCs infusion to ameliorate HFD-induced hyperglycaemia in T2DM rats. Methods: We created a T2DM rat model using a combination of a high-fat diet (HFD) and streptozotocin (STZ) administration. Then, we administered SH-MSCs injection at doses of 250 and 500 µL and assessed the therapeutic effects of SH-MSCs. We also investigated the potential underlying mechanisms involved. Results: The administration of SH-MSCs improved hyperglycemia in rats with T2DM. Infusion of SH-MSCs at 500 µL dose decreased homeostatic model assessment for insulin resistance (HOMA-IR). Histological analysis revealed that injection of SH-MSCs alleviated morphological damage of pancreas. SH-MSCs administration also inhibit the level of IL-6 and promote the expression of CD163 type 2 macrophage. Conclusion: The results of our study indicate that SH-MSCs have the potential to improve hyperglycemia and exert a protective effect on T2DM rats. HIGHLIGHTS Administration of SH-MSCs effectively improved hyperglycemia and decreased insulin resistance in TD2M rats through modulation of IL-6 levels and promotes the expression of CD163 type 2 macrophage Histological analysis demonstrated the protective effect of SH-MSCs on pancreatic morphology SH-MSCs hold promise for improving hyperglycemia, insulin resistance, and providing a protective effect in TD2M GRAPHICAL ABSTRACT

查看原文本刊更多论文

低氧预处理间充质干细胞的分泌组能改善 2 型糖尿病大鼠的高血糖症状

简介2 型糖尿病（T2DM）是一种常见的糖尿病，影响着 90% - 95% 的糖尿病患者。胰岛素增敏剂和胰岛素外源供应可暂时缓解高血糖，但同时也会产生副作用。因此，需要新的方法来同时解决胰岛素抵抗和β细胞再生问题。缺氧间充质干细胞（SH-MSCs）的分泌组含有各种生长因子和抗炎细胞因子，有可能增强胰岛素抵抗和改善胰腺功能。研究目的在本研究中，我们通过输注 SH-MSCs 来改善 HFD 诱导的 T2DM 大鼠高血糖。方法我们采用高脂饮食（HFD）和链脲佐菌素（STZ）联合给药的方法建立了 T2DM 大鼠模型。然后，我们注射了 250 微升和 500 微升剂量的 SH-间充质干细胞，并评估了 SH-MSCs 的治疗效果。我们还研究了其中潜在的内在机制。结果注射 SH-MSCs 可改善 T2DM 大鼠的高血糖症状。500微升剂量的SH-间充质干细胞输注可降低胰岛素抵抗的静态模型评估（HOMA-IR）。组织学分析表明，注射 SH-MSCs 可减轻胰腺的形态损伤。注射 SH-MSCs 还能抑制 IL-6 水平，促进 CD163 2 型巨噬细胞的表达。结论我们的研究结果表明，SH-间充质干细胞具有改善高血糖的潜力，并对 T2DM 大鼠具有保护作用。组织学分析表明 SH-MSCs 对胰腺形态有保护作用SH-MSCs 有望改善 TD2M 大鼠的高血糖、胰岛素抵抗并提供保护作用GGRAPHICAL ABSTRACT

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in Sciences

CiteScore

1.20

自引率

0.00%

发文量